[시장보고서]안티트롬빈 시장 규모, 점유율 및 동향 분석 보고서 : 용도별, 원료별, 유형별, 지역별, 부문 예측(2025-2033년)

안티트롬빈 시장 규모, 점유율 및 동향 분석 보고서 : 용도별, 원료별, 유형별, 지역별, 부문 예측(2025-2033년)

Antithrombin Market Size, Share & Trends Analysis Report By Application (Therapeutics, Diagnostics), By Source (Human, Recombinant Goat Milk), By Type, By Region, And Segment Forecasts, 2025 - 2033

상품코드 : 1870009

리서치사 : Grand View Research

발행일 : 2025년 10월

페이지 정보 : 영문 100 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,902,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,399,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,391,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

안티트롬빈 시장 요약

세계의 안티트롬빈 시장 규모는 2024년 6억 5,840만 달러로 평가되었고, 2033년까지 9억 9,720만 달러에 이를 것으로 예측됩니다.

2025년부터 2033년까지 연평균 복합 성장률(CAGR) 4.7%를 나타낼 전망입니다. 심부정맥혈전증, 폐색전증, 유전성 안티트롬빈 결핍증 등 응고장애의 유병률 상승이 주로 안티트롬빈 시장의 성장을 견인하고 있습니다.

또한 혈전증 위험을 높이는 외과 수술, 외상 사례, 임신 중 합병증 증가도 안티트롬빈 요법 수요 증가에 기여하고 있습니다. 안티트롬빈 산업은 혈전 색전증 및 응고 장애의 꾸준한 증가, 유전성 안티트롬빈 결핍에 대한 인식 증가, 조기 항응고 치료의 중요성에 의해 견인되고 있습니다. 미국에서는 매년 90만명이 정맥 혈전 색전증(VTE)의 영향을 받고 있으며, 입원 중·퇴원 직후, 암 치료 중 임신 중 개인이 특히 높은 위험에 노출되고 있습니다. 추정 6만-10만명의 미국인이 매년 VTE에 의해 목숨을 잃고 있으며, 더 많은 사람들이 장기적인 합병증을 경험하고 있습니다. 이 상황은 효과적인 예방과 관리의 필요성이 매우 중요하다는 것을 암시합니다.

수술 증가, 외상 사고, 임신 관련 합병증 증가로 인해 안티트롬빈 요법에 대한 수요가 더욱 높아지고 있습니다. 세계적으로 이용 가능한 치료 옵션에는 혈장 유래 제제와 재조합 제제가 있어, 안전성·순도가 높고 감염 위험이 낮은 재조합 제품이 널리 받아들여지고 있습니다. 바이오테크놀러지의 진보와 규제 당국의 승인을 배경으로, 집중 치료·심장 외과 수술·산과 영역에서의 사용 확대가 세계의 안티트롬빈 시장을 계속 견인하고 있습니다.

지역 시장 대시보드
지역별 시장 점유율 분석(2024년 및 2030년)
지역별 안티트롬빈 시장 : 주요 포인트
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 스웨덴
- 덴마크
- 노르웨이
아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제8장 경쟁 구도

주요 시장 진출기업에 의한 최근의 동향과 영향 분석
기업/경쟁의 분류
벤더 상황
기업 프로파일
- CSL
- Grifols, SA
- Takeda Pharmaceutical Company Limited.
- Octapharma AG
- LFB
- ENDPOINT HEALTH, INC.
- Siemens Healthineers AG
- Thermo Fisher Scientific Inc.
- Medix Biochemica

KTH

영문 목차

영문목차

Antithrombin Market Summary

The global antithrombin market size was estimated at USD 658.4 million in 2024 and is projected to reach USD 997.2 million by 2033, growing at a CAGR of 4.7% from 2025 to 2033. The rising prevalence of coagulation disorders such as deep vein thrombosis, pulmonary embolism, and hereditary antithrombin deficiency primarily drives the antithrombin market.

Increasing surgical procedures, trauma cases, and complications during pregnancy that elevate thrombosis risk are also contributing to higher demand for antithrombin therapy. The antithrombin industry is driven by the steady rise of thromboembolic and coagulation disorders, growing awareness of hereditary antithrombin deficiency, and the importance of early anticoagulant therapy. In the U.S, 900,000 people are affected by venous thromboembolism (VTE) each year, with individuals at particularly high risk during or just after hospitalization, cancer treatment, or pregnancy. An estimated 60,000 to 100,000 Americans die annually from VTE, while many others experience long-term complications, thus highlighting the critical need for effective prevention and management.

Increasing surgical procedures, trauma incidents, and pregnancy-related complications have further amplified the demand for antithrombin therapy. Treatment options worldwide include plasma-derived and recombinant formulations, with recombinant products gaining wider acceptance due to higher safety, purity, and reduced infection risks. The expansion of their use in critical care, cardiac surgeries, and obstetric cases, supported by advancements in biotechnology and favorable regulatory approvals, continues to propel the global antithrombin market forward.

Global Antithrombin Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antithrombin market report based on application, source, type, and region:

Application Outlook (Revenue, USD Million, 2021 - 2033)
Therapeutics
Diagnostics
Research
Other
Source Outlook (Revenue, USD Million, 2021 - 2033)
Human
Recombinant Goat Milk
Others
Type Outlook (Revenue, USD Million, 2021 - 2033)
Anticoagulant
Antiplatelet
Thrombolytic Drugs
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Application
- 1.2.2. Source
- 1.2.3. Type
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Source
1.9. List of Primary Source
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Application outlook
- 2.2.2. Source outlook
- 2.2.3. Type outlook
- 2.2.4. Regional outlook
2.3. Competitive Insights

Chapter 3. Antithrombin Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
3.3. Antithrombin Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Technological landscape
  - 3.3.2.3. Economic landscape

Chapter 4. Antithrombin Market: Application Estimates & Trend Analysis

4.1. Application Segment Dashboard
4.2. Antithrombin Market: Application Movement Analysis
4.3. Global Antithrombin Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
- 4.3.1. Therapeutics
  - 4.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.3.2. Diagnostics
  - 4.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.3.3. Research
  - 4.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.3.4. Other
  - 4.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Antithrombin Market: Source Estimates & Trend Analysis

5.1. Source Segment Dashboard
5.2. Antithrombin Market: Source Movement Analysis
5.3. Global Antithrombin Market Size & Trend Analysis, by Source, 2021 to 2033 (USD Million)
- 5.3.1. Human
  - 5.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 5.3.2. Recombinant Goat Milk
  - 5.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 5.3.3. Others
  - 5.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Antithrombin Market: Type Estimates & Trend Analysis

6.1. Type Segment Dashboard
6.2. Antithrombin Market: Type Movement Analysis
6.3. Global Antithrombin Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
- 6.3.1. Anticoagulant
  - 6.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 6.3.2. Antiplatelet
  - 6.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 6.3.3. Thrombolytic Drugs
  - 6.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Antithrombin Market: Regional Estimates & Trend Analysis

7.1. Regional Market Dashboard
7.2. Regional Market Share Analysis, 2024 & 2030
7.3. Antithrombin Market by Region: Key Takeaways
7.4. North America
- 7.4.1. U.S.
  - 7.4.1.1. Key country dynamics
  - 7.4.1.2. Regulatory framework/ reimbursement structure
  - 7.4.1.3. Competitive scenario
  - 7.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4.2. Canada
  - 7.4.2.1. Key country dynamics
  - 7.4.2.2. Regulatory framework/ reimbursement structure
  - 7.4.2.3. Competitive scenario
  - 7.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4.3. Mexico
  - 7.4.3.1. Key country dynamics
  - 7.4.3.2. Regulatory framework/ reimbursement structure
  - 7.4.3.3. Competitive scenario
  - 7.4.3.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
7.5. Europe
- 7.5.1. UK
  - 7.5.1.1. Key country dynamics
  - 7.5.1.2. Regulatory framework/ reimbursement structure
  - 7.5.1.3. Competitive scenario
  - 7.5.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.2. Germany
  - 7.5.2.1. Key country dynamics
  - 7.5.2.2. Regulatory framework/ reimbursement structure
  - 7.5.2.3. Competitive scenario
  - 7.5.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.3. France
  - 7.5.3.1. Key country dynamics
  - 7.5.3.2. Regulatory framework/ reimbursement structure
  - 7.5.3.3. Competitive scenario
  - 7.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.4. Italy
  - 7.5.4.1. Key country dynamics
  - 7.5.4.2. Regulatory framework/ reimbursement structure
  - 7.5.4.3. Competitive scenario
  - 7.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.5. Spain
  - 7.5.5.1. Key country dynamics
  - 7.5.5.2. Regulatory framework/ reimbursement structure
  - 7.5.5.3. Competitive scenario
  - 7.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.6. Sweden
  - 7.5.6.1. Key country dynamics
  - 7.5.6.2. Regulatory framework/ reimbursement structure
  - 7.5.6.3. Competitive scenario
  - 7.5.6.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.7. Denmark
  - 7.5.7.1. Key country dynamics
  - 7.5.7.2. Regulatory framework/ reimbursement structure
  - 7.5.7.3. Competitive scenario
  - 7.5.7.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.8. Norway
  - 7.5.8.1. Key country dynamics
  - 7.5.8.2. Regulatory framework/ reimbursement structure
  - 7.5.8.3. Competitive scenario
  - 7.5.8.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
7.6. Asia Pacific
- 7.6.1. China
  - 7.6.1.1. Key country dynamics
  - 7.6.1.2. Regulatory framework/ reimbursement structure
  - 7.6.1.3. Competitive scenario
  - 7.6.1.4. China market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.2. India
  - 7.6.2.1. Key country dynamics
  - 7.6.2.2. Regulatory framework/ reimbursement structure
  - 7.6.2.3. Competitive scenario
  - 7.6.2.4. India market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.3. Japan
  - 7.6.3.1. Key country dynamics
  - 7.6.3.2. Regulatory framework/ reimbursement structure
  - 7.6.3.3. Competitive scenario
  - 7.6.3.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.4. Australia
  - 7.6.4.1. Key country dynamics
  - 7.6.4.2. Regulatory framework/ reimbursement structure
  - 7.6.4.3. Competitive scenario
  - 7.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.5. South Korea
  - 7.6.5.1. Key country dynamics
  - 7.6.5.2. Regulatory framework/ reimbursement structure
  - 7.6.5.3. Competitive scenario
  - 7.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.6. Thailand
  - 7.6.6.1. Key country dynamics
  - 7.6.6.2. Regulatory framework/ reimbursement structure
  - 7.6.6.3. Competitive scenario
  - 7.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
7.7. Latin America
- 7.7.1. Brazil
  - 7.7.1.1. Key country dynamics
  - 7.7.1.2. Regulatory framework/ reimbursement structure
  - 7.7.1.3. Competitive scenario
  - 7.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
- 7.7.2. Argentina
  - 7.7.2.1. Key country dynamics
  - 7.7.2.2. Regulatory framework/ reimbursement structure
  - 7.7.2.3. Competitive scenario
  - 7.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
7.8. MEA
- 7.8.1. South Africa
  - 7.8.1.1. Key country dynamics
  - 7.8.1.2. Regulatory framework/ reimbursement structure
  - 7.8.1.3. Competitive scenario
  - 7.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
- 7.8.2. Saudi Arabia
  - 7.8.2.1. Key country dynamics
  - 7.8.2.2. Regulatory framework/ reimbursement structure
  - 7.8.2.3. Competitive scenario
  - 7.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
- 7.8.3. UAE
  - 7.8.3.1. Key country dynamics
  - 7.8.3.2. Regulatory framework/ reimbursement structure
  - 7.8.3.3. Competitive scenario
  - 7.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
- 7.8.4. Kuwait
  - 7.8.4.1. Key country dynamics
  - 7.8.4.2. Regulatory framework/ reimbursement structure
  - 7.8.4.3. Competitive scenario
  - 7.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
- 8.3.1. Key company heat map analysis, 2024
8.4. Company Profiles
- 8.4.1. CSL
  - 8.4.1.1. Company overview
  - 8.4.1.2. Financial performance
  - 8.4.1.3. Product benchmarking
  - 8.4.1.4. Strategic initiatives
- 8.4.2. Grifols, S.A.
  - 8.4.2.1. Company overview
  - 8.4.2.2. Financial performance
  - 8.4.2.3. Product benchmarking
  - 8.4.2.4. Strategic initiatives
- 8.4.3. Takeda Pharmaceutical Company Limited.
  - 8.4.3.1. Company overview
  - 8.4.3.2. Financial performance
  - 8.4.3.3. Product benchmarking
  - 8.4.3.4. Strategic initiatives
- 8.4.4. Octapharma AG
  - 8.4.4.1. Company overview
  - 8.4.4.2. Financial performance
  - 8.4.4.3. Product benchmarking
  - 8.4.4.4. Strategic initiatives
- 8.4.5. LFB
  - 8.4.5.1. Company overview
  - 8.4.5.2. Financial performance
  - 8.4.5.3. Product benchmarking
  - 8.4.5.4. Strategic initiatives
- 8.4.6. ENDPOINT HEALTH, INC.
  - 8.4.6.1. Company overview
  - 8.4.6.2. Financial performance
  - 8.4.6.3. Product benchmarking
  - 8.4.6.4. Strategic initiatives
- 8.4.7. Siemens Healthineers AG
  - 8.4.7.1. Company overview
  - 8.4.7.2. Financial performance
  - 8.4.7.3. Product benchmarking
  - 8.4.7.4. Strategic initiatives
- 8.4.8. Thermo Fisher Scientific Inc.
  - 8.4.8.1. Company overview
  - 8.4.8.2. Financial performance
  - 8.4.8.3. Product benchmarking
  - 8.4.8.4. Strategic initiatives
- 8.4.9. Medix Biochemica
  - 8.4.9.1. Company overview
  - 8.4.9.2. Financial performance
  - 8.4.9.3. Product benchmarking
  - 8.4.9.4. Strategic initiatives

한글목차

안티트롬빈 시장 요약

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 안티트롬빈 시장의 변수, 동향, 범위

제4장 안티트롬빈 시장 : 용도 추정·동향 분석

제5장 안티트롬빈 시장 : 원료별 추정·동향 분석

제6장 안티트롬빈 시장 : 유형별 추정·동향 분석

제7장 안티트롬빈 시장 : 지역별 추정·동향 분석